mrd evaluation in myeloma: the future is here
Published 10 years ago • 707 plays • Length 21:08Download video MP4
Download video MP3
Similar videos
-
19:40
mrd evaluation in myeloma: a necessary clinical tool?
-
23:32
approaching mrd in multiple myeloma
-
19:41
multiple myeloma: minimal residual disease
-
21:18
myeloma debate: is mrd ready for prime time? - yes
-
3:22
the main prognostic factors and why minimal residual disease is becoming crucial in multiple myeloma
-
20:55
update on mrd, new approaches and clinical value in myeloma
-
10:19
myeloma debate: is mrd ready for prime time? - no
-
1:33:39
the relevance of mrd assessment in the clinical management of multiple myeloma (mm) patients
-
22:55
future therapies in multiple myeloma
-
11:23
challenges and future perspectives for minimal residual disease (mrd) in multiple myeloma
-
1:26
mrd in myeloma: the fda perspective
-
8:42
assessing mrd in multiple myeloma
-
2:57
when is the optimal time to measure minimal residual disease (mrd) in myeloma patients?
-
4:10
where does mrd belong as a tool in myeloma?
-
14:14
debate: is mrd the new primary goal for multiple myeloma treatment? - no
-
16:08
debate: is mrd the new primary goal for multiple myeloma treatment? - yes
-
5:18
the value of mrd as a prognostic tool in myeloma
-
3:40
what’s new in minimal residual disease (mrd) detection in myeloma?
-
2:28
what is minimal residual disease (mrd) and how can it help speed up new myeloma drug approvals?